可溶性内皮因子的水平变化与子痫前期发病的关系

目的:检测正常妊娠与子痫前期患者不同孕周的血清可溶性内皮因子(soluble endoglin,sEng)水平,探讨其在子痫前期发病中的作用?方法:检测并比较31例轻度子痫前期患者?26例重度子痫前期患者及43例正常妊娠妇女sEng的血清学水平?结果:孕12~16周?孕20~24周?孕28~32周?孕37~41周,sEng在正常妊娠组浓度为(7.7 ± 1.5)?(8.2 ± 1.6)?(9.3 ± 1.7)?(11.4 ± 2.6) ng/ml;轻度子痫前期组为(7.8 ± 1.5)?(9.4 ± 1.8)?(14.2 ± 2.9)和(21.1 ± 3.7) ng/ml;重度子痫前期组为(7.9 ± 1.6)?(12.5 ± 2.8)?(25.2 ± 3.9)?(33.6 ± 4.5) ng/ml?除孕12~16周,各组sEng水平差异无显著性意义(P > 0.05);孕20~24周?孕28~32周?孕37~41周,轻度与重度组sEng水平均显著高于正常妊娠组水平(P < 0.01)?结论:孕妇血清中sEng水平变化与子痫前期发病及病情发展有关?

Relationship between alterations of soluble endoglin in maternal serum and pathogenesis of patients with preeclampsia

Objective: To detect serum levels of soluble endoglin (sEng) during different periods in normal pregnancy and patients with preeclampsia and evaluate its role in the pathogenesis of preeclampsia. Methods: Women were enrolled in following groups:healthy pregnant control(n = 43) and preeclampsia patients,which contained mild preeclampsia(n = 31),severe preeclampsia (n = 26). The serum sEng levels were measured by enzyme linked immunoassay (ELISA). Results: The concentration of sEng in control group during 12~16,20~24,28~32 and 37~41 weeks were (7.7 ± 1.5),(8.2 ± 1.6),(9.3 ± 1.7) and (11.4 ± 2.6) ng/ml,respectively. They were(7.8 ± 1.5),(9.4 ± 1.8),(14.2 ± 2.9),(21.1 ± 3.7) ng/ml in mild preeclampsia group,and(7.9 ± 1.6),(12.5 ± 2.8),(25.2 ± 3.9),(33.6 ± 4.5) ng/ml in severe preeclampsia group,respectively. The levels of maternal plasma sEng were significantly higher in the preeclamptic women than in normal controls during the latter three periods(P < 0.01) except for the first period. Conclusion: Alterations in the levels of sEng in maternal serum were associated with the occurrence and development of preeclampsia.